Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group.

Abstract

OBJECTIVE:

To describe the clinical course of patients with angioimmunoblastic lymphadenopathy (AILD)-type lymphoma with a sequential treatment with prednisone and COPBLAM/IMVP-16.

DESIGN:

A multicenter, prospective, nonrandomized trial.

SETTING:

University medical centers and community hospitals.

PATIENTS:

Sixty-seven patients were registered, 28 were excluded, and 39 patients were evaluable for response (median age, 59 years; range, 25 to 82 years) (stages I and II, 10%; stages III and IV, 90%; B symptoms, 74%).

MEASUREMENTS:

Response, survival, and relapse.

INTERVENTION:

Patients initially received prednisone and no further treatment if a complete remission was achieved. Relapsing or refractory patients were treated with COPBLAM/IMVP-16. Patients with life-threatening tumor progression or extension received COPBLAM/IMVP-16 initially. Treatments were chosen in accordance with tumor extension and response to prednisone. Treatment modalities were not compared.

RESULTS:

Twenty-eight patients received primary prednisone, 18 received secondary prednisone, and 11 received primary chemotherapy. The complete response rates (with 95% CIs) were 29% (CI, 12% to 46%), 56% (CI, 33% to 79%), and 64% (CI, 36% to 92%), respectively. The median observation time of surviving patients was 28 months (range, 7 to 53). The median overall survival time was 15 months. The probabilities (with 95% CIs) of overall survival, event-free survival, and relapse at 36 months were 40.5% (CI, 24% to 56%), 32.3% (CI, 17% to 47%), and 34.6% (CI, 14% to 56%), respectively. At the time of evaluation, 22 of 39 patients had died, 7 of noninfectious complications and 14 of infections.

CONCLUSIONS:

Prednisone with or without COPBLAM/IMVP-16 treatment in AILD-type lymphoma leads to complete remissions in about half of the patients and in long-term, disease-free survival for one third.

• Authors: W Siegert, A Agthe, H Griesser, R Schwerdtfeger, G Brittinger, M Engelhard, R Kuse, M Tiemann, K Lennert, D Huhn
• Journal: Annals of internal medicine (Ann Intern Med) Vol. 117 Issue 5 Pg. 364-70 (Sep 01 1992) ISSN: 0003-4819 [Print] United States
• PMID: 1380221 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Bleomycin
• Procarbazine
• Vincristine
• Etoposide
• Doxorubicin
• Cyclophosphamide
• Ifosfamide
• Prednisone
• Methotrexate

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bleomycin (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Etoposide (administration & dosage)
• Female
• Humans
• Ifosfamide (administration & dosage)
• Immunoblastic Lymphadenopathy (drug therapy)
• Lymphoma, T-Cell (drug therapy)
• Male
• Methotrexate (administration & dosage)
• Middle Aged
• Prednisone (administration & dosage, therapeutic use)
• Procarbazine (administration & dosage)
• Prospective Studies
• Survival Analysis
• Vincristine (administration & dosage)